AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.17bn
- $7.69bn
- $3.02bn
Brief: Amneal Receives U.S. FDA Approval For Epinephrine Injection
Brief: Amneal Announces Positive Interim Phase 4 Elevate-Pd Results With Crexont For Parkinson’S Disease
AT&T sues generic drugmakers over alleged price-fixing scheme
U.S. STOCKS ON THE MOVE-CrowdStrike Holdings, Procter & Gamble, Ford Motor
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing
U.S. STOCKS ON THE MOVE-Janux Therapeutics, Bunge Global, Shopify
Brief: Amneal Receives U.S. FDA Approval For Albuterol Sulfate Inhalation Aerosol
Amneal rises after US FDA nod for generic asthma inhaler
Brief: Amneal Receives U.S. FDA Approval For Iohexol Injection
U.S. RESEARCH ROUNDUP- Amazon, Apple, Cigna
Amneal Pharmaceuticals' Q3 revenue beats estimates, raises guidance for adjusted EBITDA
Brief: Kashiv Biosciences submits Biologics License Application to the U.S. FDA and receives European Medicines Agency acceptance for ADL-018
Brief: Amneal Announces BLA Submission Of Biosimilar Candidate To Xolair® (Omalizumab)
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
U.S. STOCKS ON THE MOVE-Opendoor Technologies, AIRO Group, Camurus
Amneal Pharma up after US FDA approves sodium oxybate solution
Brief: Amneal Receives U.S. FDA Approval Of Sodium Oxybate Oral Solution
Colorado must face Teva's lawsuit over free allergy pen law
Brief: Amneal Receives U.S. FDA Approval For Risperidone Extended-Release Injectable Suspension